Foundayo vs Zepbound: Daily Pill vs Weekly Injection
Foundayo vs Zepbound: orforglipron pill vs tirzepatide injection — mechanism, trial weight-loss themes and side effects. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Zepbound is tirzepatide, a weekly injectable GLP-1/GIP dual agonist. Foundayo is orforglipron, a once-daily non-peptide pill that activates GLP-1 only and has no food or water timing rules. In separate 72-week trials analysed the same way (all randomised participants, regardless of stopping), average weight loss at the highest dose was 20.9% with tirzepatide in SURMOUNT-1 (placebo 3.1%) and 11.2% with orforglipron in ATTAIN-1 (placebo 2.1%). Different trials and populations, not a head-to-head result. Both share GLP-1-class GI side effects. Choice depends on preference for a pill vs injection, tolerability, coverage and a prescriber's judgement. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Side by side
Last reviewed October 15, 2026.
| Foundayo | Zepbound | |
|---|---|---|
| Active ingredient | Orforglipron (small molecule) | Tirzepatide (peptide) |
| Targets | GLP-1 | GLP-1 and GIP |
| Form | Daily pill, no food timing rules | Weekly injection |
| FDA approval for weight | April 1, 2026 | November 2023 |
| Key trial weight loss | 11.2% vs 2.1% placebo at 72 weeks (ATTAIN-1) | 20.9% vs 3.1% placebo at 72 weeks (SURMOUNT-1) |
| Stopped for side effects | About 10% in ATTAIN-1 | About 6% at the highest dose in SURMOUNT-1 |
| Other approved uses | Weight management | Weight management; obstructive sleep apnoea with obesity |
Who might lean which way
Trials suggest more average weight loss with Zepbound, while Foundayo avoids injections and the fasting routine of the Wegovy pill. Coverage, side-effect tolerance and personal preference all matter; the choice is a prescriber's with the patient. See Foundayo and Zepbound side effects.
What users report here
Anonymous accounts are collected on the Tirzepatide reports. They are personal stories, often with other compounds in the mix, not evidence of effect.
Related topics
related peptides:
community guides:
More confessions from the archive
Community Q&A
- Is Foundayo a peptide?
- No. Orforglipron is a small-molecule GLP-1 receptor agonist, which is why it can be taken as a pill without fasting rules.
- Is Foundayo as effective as Zepbound?
- Separate trials showed lower average weight loss for orforglipron than tirzepatide. No direct head-to-head has been published.
- Can you switch from Zepbound to Foundayo?
- That is a prescriber decision. Lilly has studied maintenance after injectable therapy, but this page does not advise switching.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Sources
- SURMOUNT-1 — Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022
- ATTAIN-1 — Wharton et al., Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med 2025
- Zepbound (tirzepatide) prescribing information — DailyMed (NLM)
- Wegovy (semaglutide) prescribing information — DailyMed (NLM)
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.